

DAFTAR PUSTAKA

- Aafren, A., Pankaj, A., & Pankaj, P. (2022). *A Study to Evaluate Risk Of Ovarian Malignancy Algorithm (ROMA) in Patients With Ovarian Masses*. India: Spring Hope Cancer Foundation & Young Oncologist Group of Asia. p: 1-4. <https://doi.org/10.1055/s-0042-1751119>
- Ahmed, A., & Abdou, A. (2019). *Diagnostic Accuracy of CA125 and HE4 In Ovarian Carcinoma Patients and The Effect of Confounders On Their Serum Levels*. Egypt: Elsevier. p: 450-60. <https://doi.org/10.1016/j.currprobcancer.2018.12.004>
- Barr, CE., Funston, G., Jeevan, D., Sundar, S., Mounce, LTA., & Crosbie, JE. (2022). *The Performance of HE4 Alone and in Combination with CA125 for Detection of Ovarian Cancer in an Enriched Primary Care Population*. MDPI. Vol 14, p: 2124. <https://doi.org/10.3390/cancers14092124>
- Bouzari, Z., Rahimi, H., Gholinia, H., Yazdani, S., Tilaki, K., & Solemaini, J. (2019). *Cancer Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), Risk of Malignancy Index (RMI), and Risk of Ovarian Malignancy Algorithm (ROMA) as Diagnostic Test in Ovarian Cancer*. Iran: International Journal Cancer Manag. P: 1-7. <https://doi.org/10.5812/ijcm.59395>
- Budiana, I., Angelina, M., & Pemayun, T. (2019). *Ovarian Cancer: Pathogenesis and Current Recommendations for Prophylactic Surgery*. Bali: Pubmed. P: 47-54. <https://doi.org/10.4274/jtggg.galenos.2018.2018.0119>
- Casanova, R., Chuang, A., Goepfert, AR., Hueppchen, N., Weiss, P., Beckmann, C., et al. (2019). *Reproductive Cycles In Beckmann and Ling's Obstetrics and Gynecology*. Philadelphia: Wolters Kluwer. Chapter 37. 8th Edition. P: 789:93.
- Chen, F., Shen, J., Wang, J., Cai, P., & Huang, Y. (2018). *Clinical Analysis of Four Serum Tumor Markers In 458 Patients With Ovarian Tumors: Diagnostic Value Of The Combined Use of HE4, CA125, CA19-9 and CEA in Ovarian Tumors*. China: Cancer Management and Research. p: 1-6. <https://doi.org/10.2147/CMAR.S155693>
- Dahlan, S. (2016). *Besar Sampel dalam Penelitian Kedokteran dan Kesehatan Seri 2 Edisi 4*. Jakarta: Epidemiologi Indonesia.
- Dewan, R., Dewan, A., Jindal, M., & Bhardawaj, M. (2019). *Diagnostic Performance Of Serum Serum Human Epididymis Protein 4 (HE4) For Prediction Of Malignancy In Ovarian Masses*. India: Asian Pacific Journal Of Cancer Prevention. P: 1-6. <https://doi.org/10.31557/APJCP.2019.20.4.1103>
- Dieguez, N., Glickman, A., Munmany, M., Casanova, G., Agusti, N., Feijoo, B., et al. (2022). *Comparison of HE4, CA125, ROMA, and CPH-I for Preoperative Assessment of Adnexal Tumors*. Swiss: MDPI. P: 1-11. <https://doi.org/10.3390/diagnostics12010226>

- Doubeni, CA., Dubeni, AR., & Myers, AE. (2018). *Diagnosis and Management of Ovarian Cancer*. USA: Indian Journal of Clinical Practice. P: 307-15. <https://pubmed.ncbi.nlm.nih.gov/27281838/>
- Dubey H, Modi M, Verma S, Sinha R, Goel H, Ranjan A, *et al.* (2022). *Role of Human Epididymis Protein 4 in Tumour Angiogenesis*. New Delhi: Intechopen, p: 1-12. <https://doi.org/10.5772/intechopen.105678>
- Dutta, DC. (2020). *Textbook of Gynecology*. London: Jaypee Brothers Medical Publisher. Chapter 1. Anatomy of The Female Pelvic Organs. New Delhi: Jaypee Brothers Medical Publishers. P:8-11.
- Elecsys. (2022). *HE4 in Standard Operating Procedure*. Roche Diagnostic GmbH, Mannheim. P: 1-6
- Ferraro, S., Panteghini, M. (2018). *Making New Biomarkers A Reality: The Case of Serum Human Epididymis Protein 4*. Italy: DeGruyter. P: 1-11. <https://doi.org/10.1515/cclm-2018-1111>
- Gaona, P., Medina, LA., & Perez, KM. (2020). *Epidemiology of Ovarian Cancer*. Chinese Clinical Oncology. 9 (4): 47. <https://doi.org/10.21037/cco-20-34>
- Gibson, E., & Mahdy, H. (2022). *Anatomy, Abdomen, and Pelvis, Ovary*. USA: EuropePMC. <https://www.ncbi.nlm.nih.gov/books/NBK545187/>
- Global Cancer Observatory. (2020). Diakses pada: <https://gco.iarc.fr/>
- Granato, T., Porpora, MG., Longo, F., Angeloni, A., Manganaro, L., & Anastasi, E. (2015). *HE4 in the Differential Diagnosis of Ovarian Masses*. Roma: Elsevier, p: 147-55. <https://doi.org/10.1016/j.cca.2015.03.047>
- Han, C., Bellone, S., Siegel, E., Altwerger, G., Menderes, G., & Bonazzolli, E. (2018). *A Novel Multiple Biomarker Panel For The Early Detection of High-Grade Serous Ovarian Carcinoma*. USA: Elsevier. p: 1-31. <https://doi.org/10.1016/j.ygyno.2018.03.050>
- Hoffman, B., Schorge, J., Bradshaw, K., Halvorson, L., Schaffer, J., & Corton, M. (2016). *Ovarian Germ Cell and Sex Cord-Stromal Tumors In Williams Gynecology*. Chapter 36. USA: McGrawHill. P: 760-9.
- Huang, J., Chen, J., & Huang, Q. (2018). *Diagnostic Value Of HE4 in Ovarian Cancer: A Meta-Analysis*. China: European Journal of Obstetrics And Gynecology and Reproductive Biology. P: 35-42. <https://doi.org/10.1016/j.ejogrb.2018.10.008>
- International Federation of Gynecology and Obstetrics (FIGO). (2014). <https://www.ajronline.org/doi/epdf/10.2214/AJR.15.15199>
- James, NE., Chichester, C., & Ribeiro, JR. (2018). *Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer In Frontiers In Oncology*. USA: Frontiers. P: 1-13. <https://doi.org/10.3389/fonc.2018.00124>
- Jiang, S., Chen, H., Dowdy, S., Fu, A., Attewell, J., Kalogera, E., *et al.* (2013). *HE4 Transcription and Splice Variants Specific Expression in Endometrial Cancer and Correlation with Patients Survival*. USA: International Journal of Molecular Science, p: 22655-77. <https://doi.org/10.3390/ijms141122655>
- Kang, K., Koh, E., Jang, J., & Kim, C. (2022). *Multiple Biomarkers Are More Accurate Than A Combination of Carbohydrate Antigen 125 And Human*

- Epididymis Protein 4 For Ovarian Cancer Screening*. Seoul: Obstetric & Gynecology Science. P: 346-54. <https://doi.org/10.5468/ogs.22017>
- Khatri, S., Jaiswal, R., & Singh, N. (2018). *Evaluation of Serum HE4 in Ovarian Tumors, Its Comparison With Serum CA125 and Correlation With Histological Subtypes*. India: Indian Journal Of Gynecology Oncology. P: 1-7. <https://doi.org/10.1007/s40944-018-0232-7>
- Kong, X., Chang, X., Cheng, H., Ma, R., Ye, X., & Cui, H. (2013). *Human Epididymis Protein 4 Inhibits Proliferation of Human Ovarian Cancer Cells Via the Mitogen-Activated Protein Kinase and Phosphoinositide 3-Kinase/AKT Pathways*. Beijing: International Journal of Gynecological Cancer. p: 427-36. <https://doi.org/10.1097/IGC.0000000000000078>
- Kumari, S. (2018). *Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review*. India: Springer, p: 382-6. <https://doi.org/10.1007/s12291-018-0786-2>
- Landen, CN., Birrer, MJ., & Sood, AK. (2008). *Early Events in the Pathogenesis of Epithelial Ovarian Cancer*. Journal of Clinical Oncology. Vol. 26, p: 995-1005. <https://doi.org/10.1200/JCO.2006.07.9970>
- Li, W., & Wang, D. (2020). *The Differential Diagnostic Value and Clinical Significance of Serum HE4 In Ovarian Disease With Elevated CA-125*. China: Springer. P: 1-7. <https://doi.org/10.1007/s00404-020-05527-0>
- Lopez, E., Kamboj, S., Chen, C., Wang, Z., Kellouche, S., & Dudal, J. (2023). *In Vitro Models of Ovarian Cancer: Bridging the Gap Between Patophysiology and Mechanistic Models*. Paris: Biomolecules. P:2-28.
- Lycke, M., Kristjansdottir, B., & Sundfeldt. (2018). *A Multicenter Clinical Trial Validating The Performance of HE4, CA125, Risk of Ovarian Malignancy Algorithm And Risk of Malignancy Index*. Swedia: Elsevier. p: 1-7. <https://doi.org/10.1016/j.ygyno.2018.08.025>
- Lycke, M., Ulfenborg, B., Lauesgaard, JM., Kristjandottir, B., & Sundfeldt, K. (2021). *Consideration Should Be Given To Smoking, Endometriosis, Renal Function (eGFR) and Age When Interpreting CA125 and HE4 in Ovarian Tumor Diagnostics*. Swedia: DeGruyter. P: 1954:62. <https://doi.org/10.1515/cclm-2021-0510>
- McKendry, K., Duff, S., Huang, Y., Redha, M., Scanlon, A., Saadeh, F., *et al.* (2020). *The Value of Human Epididymis 4, D-dimer, and Fibrinogen Compared With CA125 Alone in Triaging Women Presenting With Pelvic Masses: A Retrospective Cohort Study*. Dublin: Wiley. p: 1-9. <https://doi.org/10.1111/aogs.14126>
- Mok, S., Kwong, J., Welch, W., Samimi, G., Ozbun, L., Bonome, T., *et al.* (2007). *Etiology and Pathogenesis of Epithelial Ovarian Cancer*. USA: 1-11. <https://doi.org/10.1155/2007/474320>
- Moore, R., Miller, M., Eklund, E., Lu, K., Bast, R., & Messerlian, G. (2012). *Serum Levels Of The Ovarian Cancer Biomarker HE4 Are Decreased In Pregnancy And Increase With Age*. Texas: American Journal Of Obstetrics & Gynecology. P: 1-7. <https://doi.org/10.1016/j.ajog.2011.12.028>
- Nezhat, F., Apostol, R., Nezhat, C., & Pejovic, T. (2015). *New Insight In The Patophysiology of Ovarian Cancer And Implication For Screening and*

- Prevention*. New York: American Journal of Obstetrics & Gynecology. P: 262-7. <https://doi.org/10.1016/j.ajog.2015.03.044>
- Olsen, M., Lof, P., Stiekema, A., Broek, D., Wilthagen, EA., Bossuyt, PM., & Lok, C. (2021). *The Diagnostic Accuracy of Human Epididymis Protein 4 (HE4) for Discriminating Between Benign and Malignant Pelvic Masses: A Systematic Review and Meta-Analysis In Acta Obstet Gynecol*, Amsterdam: AOGS, p: 1-12. <https://doi.org/10.1111/aogs.14224>
- Padubidri, VG., & Daftary, SN. (2015). *Anatomy In Shaw's Textbook of Gynecology 16th edition*. India: Elsevier. p: 11-3.
- Prskalo, Z., Bulic, P., Langer, S., Gace, M., Puljiz, M., Danolic, D., et al. (2018). *Proofs For Implementation of Higher HE4 and ROMA Index Cut Off Values In Ovarian Cancer Preoperative Stratification*. Kroasia: Taylor & Francis Group. P: 1-8. <https://doi.org/10.1080/01443615.2018.1476471>
- Qing, X., Liu, L., & Mao, X. (2022). *A Clinical Diagnostic Value Analysis of Serum CA125, CA199, And HE4 In Women With Early Ovarian Cancer: Systematic Review and Meta-Analysis*. China: Hindawi. P: 1-10. <https://doi.org/10.1155/2022/9339325>
- Reid, BM., Permuth, JB., & Sellers, TA. (2017). *Epidemiology of Ovarian Cancer: A review*. USA: Cancer Biology & Medicine. p: 9-32. <https://doi.org/10.20892/j.issn.2095-3941.2016.0084>
- Rius, M., Fuste, P., Ros, C., Zamora, A., deGuirior, C., Gracia, M., et al. (2021). *HE4 Might Be A More Useful Tumor Biomarker To Detect Malignancy In Patients With Ovarian Endometrioma When Malignancy Is Suspected*. Barcelona: Journal Of International Medical Research. p: 1-9. <https://doi.org/10.1177/03000605211047701>
- Saed, G., Morris, R., & Fletcher, N. (2018). *New Insights Into The Pathogenesis of Ovarian Cancer: Oxidative Stress*. USA: IntechOpen. P: 83-110. <https://doi.org/10.5772/intechopen.73860>
- Shin, K., Kim, H., Kwon, B., Suh, D., Joo, J., & Kim, K. (2020). *Clinical Usefulness of Cancer Antigen 125, Human Epididymis 4, and CA72-4 Level and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors In Korean Patients With and Without Endometriosis*. Busan: AnnLabMed. P: 40-7. <https://doi.org/10.3343/alm.2020.40.1.40>
- Solone, M., Hillard, P. (2020). *Adult Gynecology: Reproductive Years In Berek & Novak's Gynecology*. Chapter 10. 16th Edition. Philadelphia: Wolter Kluwer. P: 484-8.
- Stewart, C., Ralyea, C., & Lockwood, S. (2019). *Ovarian Cancer: An Integrated Review*. North Carolina: Elsevier. P: 1-6. <https://doi.org/10.1016/j.soncn.2019.02.001>
- Suri, A., Perumal, V., Ammalli, P., Suryan, V., & Bansal, S. (2021). *Diagnostic Measures Comparison For Ovarian Malignancy Risk In Epithelial Ovarian Cancer Patients: A Meta-Analysis*. New Delhi: Nature Portfolio. P: 1-14. <https://doi.org/10.1038/s41598-021-96552-9>
- Varga, J. (2021). *Ovarian Cancer Tumour Biology: Genesis*. Slovakia: IntechOpen. P:1-16.

- Wang, H., Liu, P., Xu, H., & Dai, H. (2021). *Early Diagnosis of Ovarian Cancer: Serum HE4, CA125, and ROMA Model*. China: Am J Transl Res. P: 14141:8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748147/>
- Wenchao, S., Jinfang, W., & Lubin, L. (2020). *Application Value of HE4, CA125 and ROMA In Diagnosis Of The Ovarian Cancer*. China: Acta MedicaMediterranea. P: 1-5. https://doi.org/10.19193/0393-6384_2020_3_277
- WHO Classification of Tumors. (2020). *Female Genital Tumors*. 5th Edition. Swiss: International Agency for Research on Cancer. P: 31-5.
- Zapardiel, I., Gorostidi, M., Ravaggi, A., Allende, MT., Silveira, M., & Macuks, R. (2016). *Utility of Human Epididymis Protein 4 Serum Marker for the Detection of Adnexal Malignancy: A Multicentric Prospective Study*. Madrid:Journal of Cancer Prevention, p:1-5. <https://doi.org/10.1097/CEJ.0000000000000259>
- Zheng, L., Qu, J., & He, F. (2016). *The Diagnosis and Pathological Value of Combined Detection of HE4 and CA125 for Patients With Ovarian Cancer*. China: De Gruyter. Vol 11. p: 125-32. <https://doi.org/10.1515/med-2016-0024>
- Zhu, L., Zhuang, H., Wang, H., Tan, M., Schwab, CL., & Deng, L. (2015). *Overexpression of HE4 Enhanced Proliferation, Invasion, and Metastasis of Ovarian Cancer In Oncotarget*, China: ImpactJournal, p: 1-16. <https://doi.org/10.18632/oncotarget.6327>

